核基质蛋白22与液基细胞学联合检测在膀胱癌诊断中地应用.pdfVIP

中文摘要 核基质蛋白 22 与液基细胞学联合检测在膀胱癌诊断中的应用 检查两者有一项阳性即为阳性，并进行下一步检查。两者皆为阴性则为阴性。在诊断 过程中，NMP22联合液基细胞学检查两者皆为阳性即为阳性，否则为阴性。 结果：尿液中NMP22对膀胱癌诊断的敏感性84.9 ％，特异性76.9 ％；液基细胞学 检查敏感性56.9 ％，特异性96.2 ％。NMP22联合液基细胞学检测，筛检敏感性94.2 ％， 诊断特异性98.1 ％。 结论：NMP22联合液基细胞学检查有较高的敏感性和特异性，其敏感性远高于 单一指标检测，特异性远高于NMP22检测，而与液基细胞学检查相差较小。联合检 测较单一指标的检测对膀胱癌具有更高的诊断价值。 关键词 核基质蛋白 22 ；液基细胞学检查；膀胱尿路上皮癌；敏感性与特异性； 肿瘤标记物 作 者：杨金辉 指导老师：薛波新 II 核基质蛋白 22 与液基细胞学联合检测在膀胱癌诊断中的应用 英文摘要 The application of NMP22 combined with liquid based cytology in the diagnosis of bladder cancer Abstract Backgroud: Bladder cancer is the most common malignancy of the urinary tract, according to statistics,every year about 386300 new cases were diagnosed with bladder cancer, and the number of annual global died of bladder cancer reaches more than 150200. In recent years, the incidence and mortality increased year by year. Bladder urothelial carcinoma of bladder cancer accounted for more than 90%, of which more than 70% fornon muscle invasive bladder cancer, tumor resection 5 years recurrence rate of 30%-80%. Multiple and high recurrence rate were the main clinical features. Therefore, early diagnosis, early treatment and prevention of recurrence is especially important. At present,cystoscopy is the gold standard for the diagnosis and monitoring of bladder cancer. But because of the invasive cystoscopy, for early tumor diagnosis is difficult and expensive to make the limited role of monitoring diagnosis an